课题基金 / 基金详情

项目摘要

项目成果

Pamela Anne Maher的其他基金

相关文献

中文摘要
翻译
摘要
英文摘要
Abstract The parent grant for this application supports a Phase I clinical trial of CMS121, a small molecule that has shown efficacy in multiple mouse models of Alzheimer's Disease and which affords a different therapeutic approach for treatment of AD in humans. In this application we request supplemental funds to cover the costs of COVID-19 mitigation procedures and COVID-19 testing of trial subjects. These processes and associated costs were not necessary at the time of application due in large part to the rollout of highly effective vaccines and declining infections but have become essential now due to repeated surges in infections and the appearance of highly infectious variants of the virus. The mitigation and testing procedures are necessary to protect the clinical and non-clinical staff, as well as trial subjects at the clinical site from COVID-19 infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
  • 批准号:
    10307970
  • 项目类别:
  • 资助金额:
    $250.32万
  • 财政年份:
    2021
  • 负责人:
    Pamela Anne Maher
  • 依托单位:
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
  • 批准号:
    10553057
  • 项目类别:
  • 资助金额:
    $25.17万
  • 财政年份:
    2021
  • 负责人:
    Pamela Anne Maher
  • 依托单位:
Using geroscience to understand and treat Alzheimer's disease
Therapeutic Relevance of Cannabinoids for Alzheimer's Disease